The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.
Chris Verslype
Research Funding - Bayer Schering Pharma
Hannah van Malenstein
No relevant relationships to disclose
Jeroen Dekervel
No relevant relationships to disclose
Petra Windmolders
No relevant relationships to disclose
Louis Libbrecht
No relevant relationships to disclose
Rudy van Eijsden
No relevant relationships to disclose
Frederik Nevens
No relevant relationships to disclose
Jos van Pelt
No relevant relationships to disclose